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Abstract: The Italian herbal products market is the most prosperous in Europe. The proof is
represented by the use of these products in several marketing categories, ranging from medicine to
nutrition and cosmetics. Market and legislation in Italy are at the same time cause and consequence
of this peculiar situation. In fact, the legislation on botanical food supplements in Italy is very
permissive and at the same time the market shows an overall satisfaction of users and strong feedback
in terms of consumption, which brings a widening use of medicinal plants, formerly the prerogative of
pharmaceuticals, to other fields such as nutrition. This review summarizes the market and normative
panorama of herbal products in Italy, highlighting the blurred boundaries of health indications,
marketing authorizations and quality controls between herbal medicines and non pharmaceutical
products, such as food supplements, cosmetics and other herbal-based “parapharmaceuticals”.
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1. Herbal Products in Italy: Overview of the Market
The Italian term “fitoterapico”, properly translated as “herbal drug” or “herbal medicine” or
“phytotherapic medicine” or “plant medicine”, up to twenty years ago strictly referred to drugs obtained
by means of extraction or other chemical or physical procedures applied to medicinal plants [1]; being
registered drugs, herbal medicinal products were all listed in the official pharmacopoeias of different
countries or in reference texts such as World Health Organization Monographs on Medicinal Plants
(volume 1 to 4) [2–5], European Scientific Cooperative On Phytotherapy (ESCOP) Monographs [6,7] or
monographs of deutsche Kommission E (Commission E) [8]. Efficacy, safety and chemical standardization
of herbal medicines were guaranteed and quality controls well defined. In Italy, during the XIV
legislature in 2002, the House of Representatives proposed a law that uniquely considered the definition,
the scope, the registration process and the quality requirements of herbal medicines [9]. Since the
late 1990s, however, a large number of herbal products, as cut or powdered plants, extracts or other
preparations, collectively defined as botanicals, entered into the market also as food, cosmetics and as
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parapharmaceuticals, term that can be used to define non pharmaceuticals products having health
benefits, such as food supplements and novel foods. Due to the increased interest, Europe started to
regulate this sector. In 1997, a regulation was issued on “Novel Food” (Regulation 258/97/CE) [10];
then, the community directive which regulates the requirements for the marketing authorization of
food supplements (Directive 2002/46/CE) [11] tried to harmonize the lists of "botanicals" used in the
food industry, but with little success because of the differences in norms between the different European
countries that make it difficult to distinguish between herbal drugs and botanicals foods supplements.
As reported by Silano and colleagues, in Europe, products containing the same botanical source
may belong to different marketing categories in the Member States, on the basis of different national
approaches, thus confirming the need for an harmonization of the current regulatory framework
concerning herbal products [12].
In Italy, the last Management Order of the Italian Ministry of Health of 14 March 2014 [13], which
updated the ministerial decree of 9 July 2012 [14], defines the botanicals that can currently be included
in food supplements.
Currently, in Italy, the number of botanicals in food supplements is very large.
Supply and demand led to a rediscovered interest from a large segment of the population towards
herbal products.
Herbal drugs, as drugs in general, in Italy have fluctuating market trends, stable on average in
the last ten years, with a positive trend in the 2015–2016 period [15]. Despite this, all herbal drugs sales
are very limited and no plant products are among the top sellers.
On the other hand, the Italian market is the most flourishing in the European scene both concerning
nutritional supplementation overall (over 2.5 billion euro in the period May 2015–May 2016, [16]) and
concerning botanical food supplements (a little less than 1 billion euro in the period May 2015–May
2016, [16]). In Italy, the botanical food supplements market is worth more than 4% of the overall
revenue produced by the pharmacy sale channel (25.4 billion euro in the period May 2015–May
2016, [16]) stably in the first place for the sale of drugs and parapharmaceuticals. The botanical
food supplements market is currently worth four times that of homeopathy and three times that of
veterinary drugs [16].
In Italy, it is possible to associate with the botanical food supplement a health claim that recognizes
a biological function, whether it be prevention, maintenance of homeostasis, or normalization of
biological parameters [17].
Other European countries are looking to harmonize these claims but also in this case with great
difficulty; the European Food Safety Authority (EFSA) today recognizes very few claims associated
with plant derivatives and these only refer to active ingredients or classes of active ingredients of
medicinal plants in well-defined dosages (for example, 5 mg/die of olive oil polyphenols expressed as
hydroxytyrosol to avoid lipoproteins peroxidation or 10 mg/die of monacolin from red yeast rice to
maintain regular blood cholesterol levels) and not, as in Italy, to the botanicals [18]. The number of
botanicals allowed in Italy as ingredients in food supplements is very large and to date includes two
lists: one, the Italian list, and another, the so-called BELFRIT (BELgium FRance ITaly) list resulting
from a collaboration between Belgium, France and Italy. Every European country defines its own list
of plants usable in food supplements and soon also the Italian Ministry of Health will define only one
list that will include most of the plants placed on the two lists.
Taking into account that food supplement marketing authorisation is impressively cheaper and
easier compared to that of herbal medicines, it is no surprise that the largest part of medicinal plants
in Italy are used as botanical food supplements, associated with health claims ranging from the
regularization of the intestinal transit, the maintenance of the immune system, to the normalization of
cholesterol levels [17,18], to only name the top-selling products, which makes it difficult to draw the
line between therapeutic and healthy functions; currently, despite a clear legal definition, the meaning
of the Italian term “fitoterapico” (phytotherapeutical) is conflicting. The Ministry of Health, in the
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section dedicated to “Fitoterapici”, still defines them as “herbal medicines” distinguishing them, in the
same ministerial note of 17 January 2013 [19], from the so-called “Prodotto di erboristeria”.
Market and legislation in Italy are at the same time cause and consequence of this peculiar
situation; it is true that the legislation on botanical food supplements in Italy is one of the most
permissive ones in Europe, which can only be compared to Spain, for the use of botanicals in food
supplements, and, at the same time, the market has given an impressively positive feedback in terms
of uniqueness of consumption in Europe, which helped to widen the use of medicinal plants in the
food field.
Part of this success could undoubtedly also be due to the fact that family physicians have
controlled budgets relating to prescription drugs that leads to prescriptions of botanical food
supplements, paid by patients, in the case of mild forms of chronic diseases and supplements, instead
of drugs reimbursed by the national Health Service. As medicinal plants taken orally are currently
also used in food supplements, those that have topical use are also interestingly utilized in functional
cosmetics, respecting the competence of regulation and purpose of use of this products.
The Italian and European scenario of the use of herbal products is hence very complex, and we
find that, over medicines, food supplements and cosmetics, botanicals could be marketed also as food,
for example spices or herbal teas, or as foods for special medical purposes (recently governed by EU
Regulation 128/2016) [20], or as novel foods (EC Regulation 258/97) [10], which identify products
intended to be consumed as food that have no sufficient tradition of Community-wide use, or, finally,
as Medical Devices (Law Decree No. 46 of 24/02/1997) [21], when the plant product can demonstrate
a sole mechanical and non-pharmacological action, such as protection of mucous membranes or skin
cooling or warming effect.
Labeling, marketing authorization, purpose of use, quality control of herbal products are linked
to the corresponding product category.
Below the normative relative to drugs, to pharmacy preparations (also defined as galenic
formulations), to food supplements and cosmetics, covering over 95% of the market for herbal products
in Italy, is reported.
2. Regulation of Herbal Products Marketed in Italy
2.1. Drugs
Article 1 of D. Lgs. 24 April 2006, n. 219 defines herbal drug or herbal medicine (it. fitoterapico)
as a medicine containing one or more herbal substances or one or more herbal preparations or one or
more herbal substances in association with one or more herbal preparations as active principles [22].
Herbal substances encompass the whole plants, parts of plants, algae, fungi, lichens, as a whole,
in pieces or cut, non-treated, usually desiccated but sometimes fresh, and some exudates that do not
undergo specific treatments, precisely defined on the base of the plant part used and its botanical name,
according to the binomial nomenclature (genus, species, variety and author). Herbal preparations
include preparations obtained from herbal substances using treatments such as grinding, pulverization,
mechanical extraction, extraction with solvents, distillation, expression, splitting up, purification,
concentration or fermentation and consist of grinded or pulverized drugs, tinctures, extracts, essential
oils, juices from squeezing out and processed exudates.
In general, a medicine can either be industrially produced or prepared by pharmacists
in drugstores.
In the European Pharmacopoeia 8th ed. and in the EC national pharmacopoeias, quality control
methods and requirements of herbal medicines are reported. Both raw materials and end products
are submitted to quality control, especially to the ones concerning the exact botanical characterisation
through pharmacognostic methods contained in the pharmacopoeias, the control of organic and
chemical contaminants, the control of fertilizer traces, heavy metals, microbial load and aflatoxins,
radioactive substances. The book “Quality control methods for medicinal plant materials” published
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by World Health Organization (WHO) also reports in detail the quality requirements of herbal
medicines [23] while the “WHO Guidelines on Good Agricultural and Collection Practices (GACP) for
Medicinal Plants” is a technical guidance on obtaining medicinal plant materials and herbal products
of good quality classified as medicines [24]. Pharmacopoeias and official reference texts unequivocally
establish drug preparation procedures and herbal medicine chemical requirements, specifying for each
product the active principles content and the analysis methods.
2.1.1. Industrial Drugs
Drugs of industrial origin must be authorized by the Italian Drugs Agency (AIFA) or by the
European Medicines Agency (EMA), which verify their quality, efficacy and safety, and they can only
be sold in drugstores.
Herbal products possessing a history of therapeutic use of at least ten years within the European
Community, with a recognised efficacy and an acceptable level of safety, are defined as well-established
use, and their marketing authorisation is regulated by article 10a of Directive 2001/83/EC [25], which
also establishes the allowed routes of administration including the oral, the parenteral, the topical
and the inhalation routes. Some examples of well-established use herbal products most sold in Italy
are: Permixon® (Serenoa repens (Bertram) Small fruits), Legalon® (Silybum marianum Gaertn. Fruits),
Nervaxon® (Hypericum perforatum L. flowering tops), Centellase® (Centella asiatica L. Urban purified
triterpenic fraction), Daflon® (micronized purified flavonoic fraction derived Citrus spp.), and Tegens®
(Vaccinium myrtillus L. fruits).
Timing and costs of marketing authorisation for well-established herbal medicinal products are
the same for every other drugs, consisting in more than ten years for preclinical and clinical trials and
millions euros of overall expenses.
If the active substances of a herbal product have been used in medicine for at least 30 years,
of which at least 15 within the EU, even if lacking the support from pre-clinical and clinical trials, it is
possible to submit the drug to the so-called traditional use registration.
The simplified procedure is contained in the Directive 2004/24/EC, amending, as regards
traditional herbal medicinal products (THMP), Directive 2001/83/EC on the Community code relating
to medicinal products for human use [24], along with the allowed routes of administration (oral, topic,
inhalation). The Committee on Herbal Medicinal Products (HMPC) of EMA gathers in monographs
scientific opinions on herbal substances and preparations, with information on recommended uses
and safe conditions, thus encouraging companies who seek a traditional use registration for their
product. EMA has published 184 community herbal monographs that contains one or more traditional
preparations. Despite this, only three THMPs are currently available in Italy; Pelargonium sidoides DC.
(Kaloba®) roots standardized extract was the first THMP registered and it is still the most sold in Italy.
Even though quality controls and manufacturing procedures required for THMP remain the same
as other herbal medicines, the simplified procedure for marketing authorisation does not oblige to
perform conventional experimental procedures, yet reviewed and considered in HMPC community
monographs. Directive 2004/24/EC implies a remarkable reduction in terms of costs, which is different
for each European country. THMP authorisation in Italy is relatively almost as expensive, but limited
to some tens of thousands euros.
2.1.2. Galenic Formulations
Italian law allows pharmacists to set up galenic formulations in the laboratory drugstore. These are
drugs prepared directly by pharmacists, and they are intended to obtain formulations and/or drugs
dosages not available as registered drugs.
Galenic formulations consist of magistral and officinal preparations.
Article 3 of D. Lgs. 24 April 2006, n. 219 [22] states that the first category includes drugs prepared
extemporarily on the basis of a medical prescription to a given patient and is disciplined by article 5 of
D. L. 17 February 1998, n. 23 [26], successively converted with some modifications by L. 94/98 [27], and
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the second contains drugs, their preparations or drug association enlisted in European Pharmacopoeia
(Ph. Eur.), national pharmacopoeias in force in the EU member states or officinal formularies and
prepared according to appropriate reference texts (i.e., pharmacopoeias). Officinal preparations are
designed to be provided directly to the patients served by that drugstore.
Officinal preparations have always to respect the Italian Pharmacopoeia (FUI) in some aspects.
Contrarily to magistral preparations, officinal ones can be set up whether they require a medical
prescription or not, even in advance but in limited quantity, provided that stocks do not exceed 3 kg
per formula. Every single batch needs to be marked with a number corresponding to its worksheet.
L. 94/98 enables physicians to prescribe magistral preparations having as active principles any
existing active substance described in the pharmacopoeia of an EU member state, as well as any active
substance contained in industrially produced medicines already authorized either in Italy or in another
EU member state, or with a revoked or unconfirmed marketing authorisation (AIC). In magistral
preparations, they can also employ any existing active substance contained in non-medicinal products
or cosmetics properly commercialized in the EU as active principles, obviously, in the first case for
oral administration and in the second for topical application. In order to safeguard public health,
the Ministry of Heath may impose bans and restrictions to magistral prescriptions. In the case of
magistral preparations with different indications from industrial product analogous, physicians have
to demonstrate the legitimacy of resorting to that specific extemporaneous preparation, provide
documentary evidence of the informed patient consent obtained, and indicate the alphanumeric code
uniquely identifying the patient in the prescription, in place of his or her name and surname. Original
or copies of the prescriptions received by pharmacists, whether repeatable or unrepeatable (Tables 4
and 5 of the Italian Pharmacopoeia), have to be sent every month to Local Health Authority (ASL),
which, in turn, sends them to the Ministry of Health.
Preparations are based on following the medical prescriptions, with monographs and rules for
proper preparation included in the FUI as references.
Galenic preparations have to be set up by the pharmacist according to Good Preparation Practices
and have to fulfill Pharmacopoeial quality requirements.
2.2. Food Supplements
Dietary supplements are defined in Directive 2002/46/EC [11], put into effect by D. Lgs. 21 May
2001, n. 169 [28], as dietary products intended to complete common diet and consist of a concentrated
source of nutritional substances or other substances that possess a nourishing or physiological effect.
Herbal ingredients (i.e., entire plants or their parts, non-treated and generally desiccated) and
herbal preparations (i.e., herbal ingredients that have undergone various treatments, such as extraction,
distillation, pressing, splitting up, purification, concentration, fermentation, grinding or pulverization),
defined as botanicals, can be included in dietary supplements.
In Italy, D. M. 9 July 2012 [14] and its update, D. M. 27 March 2014 [13], discipline the use
of herbal ingredients and preparations in dietary supplements. D. M. 9 July 2012 supports and
integrates D. Lgs. 21 May 2004, n. 169, fulfillment of Directive 2002/46/EC, which provides indications
for harmonization of vitamins and minerals only, letting herbal products be governed by national
legislation of each member state and by the mutual recognition principle. D. M. 27 March 2014 adds to
a preceding national list of about 1200 botanicals approved in dietary supplements (attachment 1 of D.
M. 9 July) the so-called BELFRIT list (attachment 1 bis of D. M. 27 March 2014), continuously being
updated and containing by itself approximately 1000 botanicals of which more than 120 are “new” for
Italy [13]. The project BELFRIT, which started on 18 April 2013 during the conference “Botanicals in
Food Supplements” held in Rome, starts with the definition of a harmonized list of admissible plants
in food supplements, sustained by current scientific evidence, and represents the first stage in order to
establish common rules, shared between European countries. Attachment 1 of D. M. 9 July, intended to
be fully replaced by the BELFRIT list in the future, reports reference indications for physiological effects
(i.e., claims) referring to the botanicals included and determined by ministerial guidelines. Pursuant
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to and by effect of Regulation (EC) n. 178/2002 [29], the Unique Commission for Diet and Nutrition
developed the Guidelines on documents supporting the use of herbal substances and preparations in
dietary supplements. The guidelines provide information about necessary documents and controls for
safety of use of those ingredients.
Bud preparations of officinal plants, well known and used in many European countries, in Italy
are mostly considered as food supplements.
Obviously, due to their pronounced pharmacological effect, some medicinal plants are not
included on the national or on the BELFRIT list (e.g., Digitalis spp., Ephedra spp., Taxus baccata L. and
Artemisia annua L.), whereas others can be used only when their when the daily intake of their active
principles is kept under strict control, essentially preventing their pharmacological action (for example,
maximum daily dose of 0.7 mg hypericin from Hypericum perforatum L., with a hyperphorin:hypericin
ratio of less than 7, maximum daily dose of 96 mg salicylates from preparations of Salix spp., maximum
daily dose of 30 mg synephrine from Citrus x aurantium subsp. amara (Link) Engl.).
Quality control of botanical food supplements is definitely different from one of the drugs and
this law is based on the Italian Ministry of Health regulations.
Quality control mandatory for botanicals used as food supplements features in particular: heavy
metals such as lead, mercury and cadmium and arsenic, microbial load and aflatoxins, pesticides,
residual solvents and radioactivity. Heavy metals and arsenic limits in botanical food supplements are
defined by the Reg. (EC) 629/08 [30] and by the self-regulation document issued by Italian Category
Associations operating on botanicals: Codex Herbarum [31]. The limits are set to be very similar
to those of herbal medicines and more rigorous regarding mercury (0.3 ppm in herbal medicines
and 0.1 ppm in botanical food supplements). Microbial load limits vary for different botanicals
(i.e., powders, powders to be used in boiling water, extracts) and consider total viable bacteria,
total yeasts count and biliar salts resistant Gram-bacterial count. Salmonella spp., Escherichia coli
and Staphylococcus aureus must be absent in every botanical food supplement. Limits for pesticides
and aflatoxins are quite similar, even if more permissive, of those of herbal medicines. In the food
field, limits of residual solvents are more restrictive than the ones for pharmaceuticals and only
food-grade solvents as water, glycerine, ethanol and, with well-defined limits, ethyl acetate is admitted
in product preparation.
In the case of a regulations gap, most references to raw materials and end products are taken or
adjusted from pharmacopoeias and assimilated to that of herbal medicines.
Moreover, dietary supplements require their nutritional values be included on the label,
their recommended daily intake and the dosage for each posological form. Within the limits explained
above, the regulation of dietary supplements does not impose specific preparation techniques allowing
for obtaining plant extracts and herbal preparations; it does not require producers to quantify
the active principles (except in the case of pre-established daily intake limits, e.g., hypericin or
synephrine) and, in any event, it does not force them to use certain methods of analysis for botanical
standardisation either. The food supplement marketing authorisation request in Italy is very cheap,
costing 160.20 euros.
2.3. Herbal Preparations
In Europe, a legal definition of the Italian term “prodotto erboristico” (herbal products) does not
exist, while the Italian definition of herbal products indicates herbal preparations intended to be only
sold to customers and exclusively packaged at the point of sales of pharmacies and parapharmacies or
in the herbalist’s shops, in the last two cases only in the presence of food laboratories authorized by
local health units. Plant preparations and derivatives can be commercialized as herbal products in
accordance with the Italian Ministry of Health notes n. 600.12/AG45.1/706 of 5 December 2002 and
DGSAN 0015807-P-19/05/2010 of 19 May 2010 [32,33]. The set-up products, considered as unpackaged,
are equated to foods and therefore they can only be assumed orally, cannot boast pharmacological
properties (drugs) or health benefits (dietary supplements) and can contain exclusively botanical
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species accepted to be used in foods, thus both plants are part of the diet and the ones included on the
national and the BELFRIT lists. Herbal products can be extemporarily prepared or stored but within
the limits established for officinal preparations, up to 3 kg.
Pharmacists set up herbal preparations according to Good Preparation Practices and to the
national legislation on food preparation, with reference to products prepared in parapharmacies and
herbalist’s shops; quality requirements of herbal products usable to prepare herbal preparations remain
the same as those of packaged botanical food supplements.
2.4. Cosmetics
Any substance or mixture intended to be placed in contact with the various external parts of
the human body (epidermis, hair, nails, lips and external genital organs) or with the teeth and the
mucous membranes of the oral cavity, with a view exclusively or mainly to cleaning them, perfuming
them, changing their appearance and/or correcting body odours and/or protecting them or keeping
them in good condition. Regulation (EC) n. 1223/2009 does not only give the definition of “cosmetic
product”, and it contains a series of rules ensuring the safety of cosmetics from different points of view
(from the manufacture method to the ingredient control, to the mandatory labelling and the expert
evaluation) [34].
Since the regulation is enforceable as law in all member states, it establishes that some of the
information on the label, such as purpose, warnings and instructions for use, have to be reported in
the official language of the country where the product is sold.
Plant products in cosmetics, as well as in dietary supplements, cannot be used with a therapeutic
aim, but with the sole purpose of maintaining skin integrity.
The inclusion of plant products in cosmetics does not imply variations in quality controls and
requirements of those products, thus the reference legislation is the one established by Regulation (EC)
n. 1223/2009 [34].
As in the case of food supplements, the marketing authorisation request for cosmetics is cheap
and affordable for companies working with herbal products.
3. Discussion
Italy has a long tradition and knowledge in the use of herbal products, and it is currently the
European country with the fastest growing market, since they are used as food, novel foods, food
supplements and cosmetics when intended to maintain health more than as herbal medicines with
therapeutic purposes.
Among the more than 50,000 herbal products available, people usually choose the ones that better
respond to their health needs, often ignoring the fact that diverse marketing categories imply deep
differences in terms of manufacturing processes, chemical composition, quality controls, studies of
efficacy and price.
The marketing authorization of herbal medicines entail the assessment of therapeutic efficacy
with preclinical and clinical studies, and the accomplishment of Good Preparation Practices and the
distribution mainly through pharmacies, under the control of an expert who can recommend their use.
All registered herbal medicines have strong scientific data support. For example, more than
150 clinical trials reporting the hepato-protective action of sylimarine from Sylibum marianum Gaertn.
fruits (Legalon®) are published in Scopus and PubMed databases; more than 60 clinical studies, instead,
regard the standardized lipidosterolic extract of Serenoa repens (Bartram) Small fruits (Permixon®),
used for benign prostatic hyperplasia.
In addition, THMPs are well studied and over 20 clinical studies have been recorded on the
standardized extract of Pelargonium sidoides DC. roots used in the case of cold symptoms.
A recent review by Minghetti and colleagues suggested the need for a simplified pharmaceutical
development procedure for herbal medicinal products with a certain grade of innovation (i.e., proposed
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for new indications), in order to increase the number of safe and effective products on the market and
to improve the therapeutic index of traditionally utilized products [35].
On the other hand, foods and food supplements only require the obligation of notification to
the Ministry of Health that ensure safety of use, while efficacy is only referred to the use of allowed
substances with health claims. Hazard Analysis and Critical Control Points (HACCP) procedures are
required to manufacture these products. In addition, efficacy is not to be proven for cosmetics.
It is important to bear in mind that, beyond being certainly easier, marketing a food supplement
is definitely cheaper than marketing an herbal medicine. This is likely to make the food supplements
market completely overwhelm the one for herbal medicines.
The quality standards in botanical food supplements vary from one product to another.
Companies are beginning to significantly improve their quality standards, often proposing extracts
and formulations increasingly similar to herbal medicines. It is even possible that herbal drugs,
marketed abroad as herbal medicine, in Italy are registered only as botanical food supplements.
The most representative cases are those of standardized extracts of Panax ginseng CA. Mayer roots
and Gingko biloba L. leaves. Obviously, the quality and the effectiveness of these “botanicals” is well
documented. Nevertheless, to avoid safety concerns and maintain the price, often botanical food
supplements containing pharmaceutical grade extracts are significantly underdosed.
Unfortunately, this notable attention to the quality still represents the smallest percentage of
botanical food supplements available in Italy, and more than 90% of ingredients and formulations sold
as botanical food supplements have not undergone clinical investigations.
In this context, it is evident that physicians and pharmacists, above all, have the correct and
rational use of parapharmaceuticals on hand, orienting users towards the choice of high quality
products that could actually be safe and effective.
Magistral and officinal galenic preparations guarantee the quality and often represent the best
choice among herbal products; nevertheless, these preparations are not often used because people
scarcely know this category of products, physicians are not often adequately trained to prescribe herbal
products and pharmacists having the opportunity to prepare galenics are limited in number.
4. Conclusions
Despite an ambiguous legislative situation that still requires a lot of work to be done, the scenario
concerning herbal products in Italy is currently very fascinating due to the ever-increasing satisfaction
of users and the constantly increasing market, which also led to a re-discovered new interest of the
international scientific community on medicinal plants. The fundamental step towards the diffusion
and spread of the use of herbal products has been initiated, in the future perspective of a more
scientific and rationale use of these products. Undoubtedly, this current phytotherapy is the medical
discipline that, being so diverse and multidisciplinary, more than many others, is geared toward
modern medicine, focused on the individual, treating not only the symptoms of disease, but also
providing benefits for the prevention of disease and health maintenance.
Author Contributions: Marco Biagi conceived, designed and wrote the manuscript; Paolo Governa and
Giulia Cettolin wrote the manuscript; Rita Pecorari, Giovanni Appendino, Elisabetta Miraldi, Anna Rosa Magnano
and Daniela Giachetti reviewed drafts of the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Giachetti, D.; Monti, L. Medicinal plants in phytotherapy. Annali Dell’istituto Superiore di Sanita 2005, 41,
17–22. [PubMed]
2. World Health Organization. WHO Monographs on Selected Medicinal Plants; World Health Organization:
Geneva, Switzerland, 1999; Volume 1.
3. World Health Organization. WHO Monographs on Selected Medicinal Plants; World Health Organization:
Geneva, Switzerland, 2002; Volume 2.
Pharmaceuticals 2016, 9, 65 9 of 10
4. World Health Organization. WHO Monographs on Selected Medicinal Plants; World Health Organization:
Geneva, Switzerland, 2007; Volume 3.
5. World Health Organization. WHO Monographs on Selected Medicinal Plants; World Health Organization:
Geneva, Switzerland, 2009; Volume 4.
6. European Scientific Cooperative on Phytotherapy. ESCOP Monographs: The Scientific Foundation for Herbal
Medicinal Products, 2nd ed.; European Scientific Cooperative on Phytotherapy: Stuttgart, Germany, 2003.
7. European Scientific Cooperative on Phytotherapy. Available online: http://escop.com (accessed on
7 September 2016).
8. Klein, S.; Rister, R.; Riggins, C. The Complete German Commission E Monographs: Therapeutic Guide to Herbal
Medicines, 1st ed.; American Botanical Council: Austin, TX, USA, 1998; pp. 36–138.
9. Ddl 3312/2003. Available online: http://www.senato.it/japp/bgt/showdoc/frame.jsp?tipodoc=Ddlpres&
leg=14&id=00135684&part=doc_dc&parse=no&stampa=si&toc=no (accessed on 7 September 2016).
10. Regulation, H.A.T. Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January
1997 concerning novel foods and novel food ingredients. Off. J. Eur. Communities 1997, 40, 1–7.
11. The European Parliament and the Council of European Union. Directive 2002/46/EC of the European
Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating
to food supplements. Off. J. Eur. Communities 2002, 45, 51–57.
12. Silano, V.; Coppens, P.; Larrañaga-Guetaria, A.; Minghetti, P.; Roth-Ehrang, R. Regulations applicable to plant
food supplements and related products in the European Union. Food Funct. 2011, 2, 710–719. [CrossRef]
[PubMed]
13. Italian Ministry of Health. D.M. 27 marzo 2014 “Aggiornamento del DM 9 luglio 2012 sulla Disciplina
dell’impiego negli integratori alimentari di sostanze e preparati vegetali”. Available online: http://www.
trovanorme.salute.gov.it/norme/dettaglioAtto?id=48636 (accessed on 7 September 2016).
14. Italian Ministry of Health. Disciplina dell’impiego negli integratori alimentari di sostanze e preparati
vegetali. Gazzetta Ufficiale della Repubblica Italiana 2012, 169. (In Italian)
15. Federchimica Data. Available online: http://www.federchimica.it (accessed on 7 September 2016).
16. Federsalus Data. Available online: http://www.federsalus.it (accessed on 7 September 2016).
17. Italian Ministry of Health. Available online: http://www.salute.gov.it (accessed on 7 September 2016).
18. European Food Safety Authority. Available online: http://www.efsa.europa.eu/it (accessed on
7 September 2016).
19. Italian Ministry of Health. Available online: http://www.salute.gov.it/portale/temi/p2_6.jsp?id=3617&
area=farmaci&menu=med (accessed on 7 September 2016).
20. The European Commission. Commission Delegated Regulation (EU) 2016/128 of 25 September 2015
supplementing Regulation (EU) No 609/2013 of the European Parliament and of the Council as regards the
specific compositional and information requirements for food for special medical purposes. Off. J. Eur. Union
2016, 59, 30–45.
21. D. Lgs 24 febbraio 1997 n. 46 “Attuazione della direttiva 93/42/CEE, concernente i dispositivi medici.”.
Gazzetta Ufficiale 1997, 54. (In Italian)
22. D. Lgs. 24 aprile 2006 n. 219 “Attuazione della direttiva 2001/83/CE (e successive direttive di modifica)
relativa ad un codice comunitario concernente i medicinali per uso umano, nonché della direttiva
2003/94/CE.”. Gazzetta Ufficiale 2006, 142. (In Italian)
23. World Health Organization. Quality Control Methods for Medicinal Plant Materials; World Health Organization:
Geneva, Switzerland, 1998.
24. World Health Organization. WHO Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal
Plants; World Health Organization: Geneva, Switzerland, 2003.
25. The European Parliament and the Council of European Union. Directive 2004/24/EC of the European
Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products,
Directive 2001/83/EC on the Community code relating to medicinal products for human use. Off. J.
Eur. Union 2004, 47, 85–90.
26. D.L. 17 febbraio 1998 n. 23 “Disposizioni urgenti in materia di sperimentazioni cliniche in campo oncologico
e altre misure in materia sanitaria.”. Gazzetta Ufficiale della Repubblica Italiana 1998, 39. (In Italian)
Pharmaceuticals 2016, 9, 65 10 of 10
27. L. 94/1998 “Conversione in legge, con modificazioni, del decreto-legge 17 febbraio 1998, n. 23, recante
disposizioni urgenti in materia di sperimentazioni cliniche in campo oncologico e altre misure in materia
sanitaria.”. Gazzetta Ufficiale della Repubblica Italiana 1998, 86. (In Italian)
28. D. Lgs. 21 maggio 2001 n. 169 “Attuazione della direttiva 2002/46/CE relativa agli integratori alimentari.”.
Gazzetta Ufficiale della Repubblica Italiana 2004, 164. (In Italian)
29. The European Parliament and the Council of European Union. Regulation (EC) No 178/2002 of the European
Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of
food law, establishing the European Food Safety Authority and laying down procedures in matters of food
saf. Off. J. Eur. Communities 2002, 45, 1–24.
30. The Commission of the European Communities. Regulation (EC) No 629/2008 of 2 July 2008 amending
Regulation (EC) No 1881/2006 setting maximum levels for certain contaminants in foodstuff. Off. J.
Eur. Union 2008, 51, 6–9.
31. Codex Herbarum. Available online: http://www.martin-bauer.it/Documents/Codex.pdf (accessed on
7 September 2016).
32. Italian Ministry of Health Note n. 600.12/AG45.1/706, 5 December 2002. Available online: http://www.
trovanorme.salute.gov.it (accessed on September 2016).
33. Italian Ministry of Health note DGSAN 0015807-P-19/05/2010, 19 May 2010. Available online:
http://www.trovanorme.salute.gov.it (accessed on September 2016).
34. The European Parliament and the Council of European Union. Regulation (EC) No 1223/2009 of the
European Parliament and of the Council of 30 November 2009 on cosmetic products. Off. J. Eur. Union 2009,
52, 59–209.
35. Minghetti, P.; Franzè, S.; Zaccara, V.; Raso, F.; Morazzoni, P. Innovation in Phytotherapy: Is a New Regulation
the Feasible Perspective in Europe? Planta Med. 2015, 82, 591–595. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
